23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Focus

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Focus.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Try Life Science Focus now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

AAX Biotech teams up with Austrian AI player on cancer antibodies

AstraZeneca snaps up vaccine technology company

FDA turns down Novocure’s brain metastases device
Advertisement
Sponsored content

30 Years of Connecting Medicon Valley
Sponsored content News from our members
Carl Zeiss AB

New issue of Precise Magazine: Explore industry insights, trends and innovations
Aurevia

Post Market Surveillance (PMS): 6 Steps to Effective PMS under MDR and IVDR
Cavidi AB

Cavidi’s BOLD Named “Proteomics Innovation of the Year” as US Patent Nears Grant
Strömberg Distribution Sverige

3PL- där kvalitet aldrig kompromissas
Aurevia

UK plans permanent recognition of CE-marked medical devices
OEM Automatic AB

Rätt ledare för rätt kabelapplikation
See all announcements

FDA approves Bayer’s first-in-class stroke drug
Advertisement

Danish biotech company raises €20 million: Closing in on clinical trials
Advertisement
In Focus

Autoinjectors gain ground across therapeutic areas: “A huge trend”

Oncopeptides secures broader EU indication for Pepaxti
Advertisement

EFN: Could AstraZeneca make a move for Sobi?
Advertisement
Advertisement
Column

Catharina Barkman: Health gains that transform lives and economies
Advertisement

Gubra seeks to double number of candidates in 2030
Interview

“That’s how it is in biotech – there are ups and downs”
Advertisement

Updated: Egetis receives SEK 5.3 billion takeover bid from US company
Advertisement

Newsletter
Advertisement Advertisement
BREAKING
{{ article.headline }}
0.029|